Business
Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver’s Digital International Liver Congress 2021
-Five scientific posters to be presented at upcoming EASL ILC meeting- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"-Five scientific posters to be presented at upcoming EASL ILC meeting- All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in H2 2021 and H1 2022, respectively-Antiviral activity data from at least one cohort of CHB patients for ALG-010133 and ALG-000184 expected to be presented in H2 2021 SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will present five abstracts highlighting data from the company’s chronic hepatitis B (CHB) therapeutic programs. The presentations will take place at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2021 (ILC 2021), which is being held virtually on June 23-26, 2021. Important information for these posters can be found below. Additionally, the company today announced a CHB portfolio update to highlight the progress made with the four development programs. Aligos reported that both its capsid assembly modulator (CAM) drug candidate and the S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS™) molecule drug candidate have now completed Phase 1a studies in healthy volunteers and are currently being evaluated in CHB patients in Phase 1b studies. We expect to present preliminary data from these Phase 1b studies in H2 2021. Once Phase 1b studies are completed, we plan to advance these drug candidates into Phase 2 studies in H2 2022 to identify combination regimens that could potentially result in enhanced rates of functional cure. Following closely behind the STOPS and CAM programs, Aligos’ antisense oligonucleotide (ASO) and small interfering RNA (siRNA) drug candidates continue to advance through nonclinical development and are on track to start Phase 1 trials in H2 2021, and H1 2022, respectively. For additional details, see the Chronic Hepatitis B Portfolio Summary below. ------------------------------------------Aligos’ upcoming poster presentations at EASL’s ILC 2021 are summarized below. S-antigen Transport-inhibiting Oligonucleotide Polymer...